Blow for Takeda's Uloric as US FDA adds new safety warning

22 February 2019

Following consideration of a post-marketing study, conducted as a condition of its 2009 approval, the US regulator has added a Boxed Warning to the label for gout therapy Uloric (febuxostat).

The US Food and Drug Administration says the study shows there is an increased risk of death with Uloric, compared to rival gout medicine allopurinol.

The safety clinical trial, conducted by the drug’s manufacturer Takeda Pharmaceutical (TYO: 4502), showed an increased risk of heart-related death and death from all causes with Uloric.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK